Shots:
- Sanofi has reported the P-II (ElevAATe) study data assessing efdoralprin alfa (Q3W or Q4W) vs SoC plasma-derived augmentation therapy (pdAAT; QW) in 97 pts with AATD-related emphysema
- Efdoralprin alfa achieved a mean increase in fAAT trough levels of 24.1μM (Q3W) & 16.8μM (Q4W) vs 7.6μM at Wk. 32, with Q3W meeting the 1EP, while all key 2EPs were also met
- In 2EPs, the mean serum fAAT average concentrations increased by 32.9μM (Q3W) & 26μM (Q4W) vs 17.9μM at Wk. 32, with Q3W maintaining fAAT levels above the normal threshold for 100% of days, while Q4W for 89.3% of days vs 40.8% over 32wks.; data were presented at ATS’26
Ref: Globenewswire | Image: Sanofi | Press Release
Related News: Sanofi Reports the CHMP Positive Opinion for Cenrifki (Tolebrutinib) to Treat Non-Relapsing SPMS
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
